



Rule Category:
Pharmaceutical

Ref: No:
2013-PH-0002

Version Control:
Version No. 2.0

Effective Date:
15 May 2013

Revision Date:
August 2015



Phenytoin Indications

Adjudication Rule

Table of content

Abstract	Scope	Adjudication Policy	Adjudication examples	Denial codes	Appendices
Page 1	Page 2	Page 2	Page 2	Page 2	Page 3

Abstract

1. For Members

Phenytoin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses in the brain that cause seizures.

Phenytoin is used to control seizures. It does not treat all types of seizures, and your doctor will determine if it is the right medication for you.

Daman covers treatment with phenytoin, if medically necessary and as policy terms and conditions of each health insurance plan administered by Daman.

2. For Medical Professionals

This guideline highlights the medical necessity and coverage of phenytoin for all the health insurance plans administered by Daman.

Phenytoin is a member of antiepileptic drug (AED); it is a hydantoin-derivative and is related to the barbiturates in chemical structure.

These medicines are used to:

1. Control all type of epilepsies except absence seizures
2. Control certain type of seizures like:
 - i. tonic-clonic (grand mal) and
 - ii. complex
 - iii. partial (psychomotor, temporal lobe) seizures
3. Control trigeminal neuralgia, the event that carbamazepine or other first-line treatment seems inappropriate and this should be documented.
4. Control status epilepticus, and
5. Control seizures that may begin during or after surgery to the brain or nervous system.

Approved by:
Daman

Responsible:
Medical Strategy &
Development Department

Related Adjudication Rules:
None

Disclaimer

By accessing these Daman Adjudication Rules (the "AR"), you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this AR is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The AR is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman AR. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This AR does not grant any rights or impose obligations on Daman. The AR and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this AR, including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This AR is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the AR as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This AR is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This AR incorporates the Current Procedural Terminology and Current Dental Terminology (CPT® and CDT®, which is a registered trademark of the American Medical Association ("AMA"), and the American Dental Association ("ADA") respectively), and the CPT and CDT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the AR at any time by providing one month prior notice.

Doc Ctrl No.:	TEMP/MSD-006	Version No.:	1	Revision No.:	0	Date of Issue:	08.05.2013	Page No(s).:	1 of 3
---------------	--------------	--------------	---	---------------	---	----------------	------------	--------------	--------

Scope

This adjudication rule specifies the coverage details of phenytoin drug for all the health insurance plans administered by Daman.

Phenytoin drug is available in the form of:

- Capsule
- Tablet
- Injection
- Oral-suspension

Adjudication Policy

Eligibility / Coverage Criteria

Phenytoin is covered for all the health insurance plans administered by Daman, if medically indicated, and subject to policy terms and conditions.

Coverage of Phenytoin for Visitor's plan will be limited to the management of Status Epilepticus in the emergency room only; as Status Epilepticus is life-threatening condition and requires emergency treatment.

Phenytoin is a member of antiepileptic drug (AED); it is a hydantoin-derivative and is related to the barbiturates in chemical structure.

These medicines are used to:

1. Control all type of epilepsies except absence seizures
2. Control certain type of seizures like
 - a. tonic-clonic (grand mal) and
 - b. complex
 - c. partial (psychomotor, temporal lobe) seizures
3. Control trigeminal neuralgia, in the event that carbamazepine or other first-line treatment seems inappropriate and this should be documented.
4. Control Status epilepticus , and
5. Control seizures that may begin during or after surgery to the brain or nervous system.

Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.

Non-Coverage

Phenytoin is covered for all the health insurance plans administered by Daman, if medically indicated, subject to policy terms and conditions.

Coverage of phenytoin for Visitor's plan will be limited to the management of status epilepticus in the emergency room only; as status epilepticus is life-threatening condition and requires emergency treatment.

Payment and Coding Rules

Please apply HAAD payment rules and regulations and relevant coding manuals for the medications.

Adjudication Examples

Example 1

Question: A 37-year-old male holding a Regional Plan, has visited the outpatient facility. He was diagnosed with generalized non-convulsive epilepsy, without mention of intractable epilepsy. He was prescribed phenytoin drug.

Answer: The claim will be rejected because phenytoin is not a drug of choice for absence seizures.

Example 2

Question: A 2 year boy diagnosed with febrile convulsions simple, unspecified was prescribed phenytoin oral suspension.

Answer: The claim will be accepted.

Denial codes

Code	Code description
MNEC-003	Service is not clinically indicated based on good clinical practice
MNEC-004	Service is not clinically indicated based on good clinical practice, without additional supporting diagnosis/activities
NCOV-003	Service(s) is (are) not covered
NCOV-002	Pre-existing conditions are not covered

Appendices

A. References

1. Parke-Davis. Dilantin (Phenytoin tablets, USP) Prescribing Information. Morris Plains, NJ; 1998 May
2. Meierkord H, Boon P, Engelsens B et al. EFNS Guideline on the Management of Status Epilepticus in Adults. *Eur J Neurol.* 2010; 17:348-55. [PubMed 20050893]
3. <http://bestpractice.bmj.com/best-practice/monograph/464/treatment/details.html>
4. Green Rain Drug List

5. Dilantin Official FDA Information, Side Effects and Uses.html
6. British National Formulary (2010). *British National Formulary*. UK: BMJ Group. 281-282; 266; 287-290.
7. NHS. (2010). NHS. Available: [Http://www.nhs.uk](http://www.nhs.uk). Last accessed 18th April 2012
8. Official FDA Information. (2010). *Phenytoin Sodium*. Available at: <http://www.drugs.com/pro/phenytoin-sodium.html/>. Last accessed 17th April 2012.
9. NICE Guidelines (2012). The Epilepsies. In: Diagnosis and Management of the Epilepsies Diagnosis in Adult and Children in Primary and Secondary Care. 8th ed. London: National Clinical Guideline Center. Full.
10. Lippincott Williams & Wilkins. (2009). Epilepsy. In: Richard A. Harvey, Pamela C. Champe *Lippincott's Illustrated Reviews: Pharmacology*. 4th ed. Florida: Lippincott William&Wilkins.p277-p294
11. AHFS Drug Information 2004. McEvoy GK, ed. Phenytoin. Bethesda, MD: American Society of Health-System Pharmacists; 2004:2117-2120.
12. Schedule of Benefits

B. Revision History

Date	Change(s)
01-07-13	V 1.1: New Template
15-07-14	1. V 2.0 2. Disclaimer updated as per system requirements